Immutep Limited
IMMP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IMMP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMMP
Immutep Limited is a development-stage biotechnology company focused on advancing its lead product candidate, eftilagimod alfa (efti), through late-stage clinical trials towards marketing approval, with no approved products or consistent revenue to date [sec · filed 2025-10-24].
Key risk: No approved products or revenue
Market Cap
$56.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2025.
Tracking 1 clinical trial for Immutep Limited.
Immutep Limited is a development-stage biotechnology company focused on advancing its lead product candidate, eftilagimod alfa (efti), through late-stage clinical trials towards marketing approval, with no approved products or consistent revenue to date [sec · filed 2025-10-24].
- Immutep has a history of significant operating losses and negative cash flows, with net losses of A$61.4 million and A$42.7 million for fiscal years 2025 and 2024, respectively [sec · filed 2025-10-24].
- The company's lead candidate, eftilagimod alfa (efti), is being advanced through late-stage clinical trials, but no product has received regulatory approval for commercial sale [sec · filed 2025-10-24].
- As of June 30, 2025, Immutep reported cash and equivalents of $67.4 million, shareholders' equity of $94.1 million, and total debt of $0.6 million [sec].
- Immutep also generates modest income from sales of LAG-3 research reagents and maintains a dedicated R&D laboratory near Paris [sec · filed 2025-10-24].
- The company expects to require substantial additional funding to achieve long-term goals and complete product development, as it does not anticipate significant revenue until regulatory approval is obtained [sec · filed 2025-10-24].
What works
- Immutep is advancing its lead product candidate, eftilagimod alfa (efti), through late-stage clinical trials, indicating progress toward potential marketing approval [sec · filed 2025-10-24].
- The company maintains a dedicated R&D laboratory near Paris and engages in external research collaborations, supporting ongoing innovation [sec · filed 2025-10-24].
- Immutep generates modest income from sales of LAG-3 research reagents, providing a small revenue stream while product candidates are in development [sec · filed 2025-10-24].
What to weigh
- Immutep has no approved medicinal products and no source of consistent material revenue, with a history of significant operating losses and negative cash flows [sec · filed 2025-10-24].
- The company faces substantial risks in clinical development, including the possibility that ongoing or future trials may not show sufficient safety or efficacy for regulatory approval [sec · filed 2025-10-24].
- Immutep expects to require substantial additional funding to complete research and development, and such financing may not be available on acceptable terms or at all [sec · filed 2025-10-24].
From the filings
Quoted directly from source documents.
Immutep has a history of operating losses and negative cash flows.
“We have experienced significant recurring operating losses and negative cash flows from operating activities since inception. For example, for the fiscal years ended June 30, 2025, and 2024, we had net losses of A$61.4 million and A$42.7 million, respectively.”
SEC filings · October 24, 2025
Immutep is advancing eftilagimod alfa (efti) through late-stage clinical trials.
“Immutep is advancing its lead product candidate, eftilagimod alfa (efti) through late-stage clinical trials towards marketing appr”
SEC filings · October 24, 2025
Immutep has no approved products and no consistent revenue.
“We have no medicinal products approved for commercial sale and no source of consistent material revenue.”
SEC filings · October 24, 2025
Immutep expects to need substantial additional funding.
“We anticipate that we will require substantial additional funds in order to achieve our long-term goals and complete the research and development of our current product candidates.”
SEC filings · October 24, 2025
Risks & what to watch (3)›
Key risks
- No approved products or revenue — Immutep has no approved medicinal products and no consistent revenue, relying on future regulatory approval for income [sec · filed 2025-10-24].
- Clinical trial failure risk — Ongoing and future trials may not show sufficient safety or efficacy to obtain regulatory approval, which would harm prospects [sec · filed 2025-10-24].
- Funding dependency — The company expects to need substantial additional funds, which may not be available on acceptable terms, potentially curtailing operations [sec · filed 2025-10-24].
What to watch
- Progress of late-stage clinical trials for eftilagimod alfa (efti) and any regulatory interactions [sec · filed 2025-10-24].
- Ability to secure additional financing through public or private offerings or licensing deals [sec · filed 2025-10-24].
- Updates on preclinical and clinical development of other candidates like IMP761 [sec · filed 2025-10-24].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Immutep Limited through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Immutep Limited facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
24
Total value held
$483K
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 810,926 | $285K |
| two sigma investments, lp | 124,760 | $44K |
| citadel advisors llc | 94,174 | $33K |
| xtx topco ltd | 73,837 | $26K |
| two sigma securities, llc | 53,590 | $19K |
| dimensional fund advisors lp | 30,409 | $11K |
| quadrature capital ltd | 26,910 | $9K |
| rhumbline advisers | 22,053 | $8K |
| jane street group, llc | 21,212 | $7K |
| millennium management llc | 20,802 | $7K |
Showing top 10 of 24 institutional holders of Immutep Limited. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 0.9%
- Days to cover
- 0.0
- Shares short
- 1,247,590
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMMP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Immutep Limited?
Immutep Limited is a development-stage biotechnology company focused on advancing its lead product candidate, eftilagimod alfa (efti), through late-stage clinical trials towards marketing approval, with no approved products or consistent revenue to date [sec · filed 2025-10-24].
Who is the CEO of Immutep Limited?
Mr. Marc Voigt is the chief executive officer of Immutep Limited (IMMP).
Where is Immutep Limited headquartered?
Immutep Limited (IMMP) is headquartered in Sydney, NSW, Australia.
What therapeutic areas does Immutep Limited focus on?
Immutep Limited develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.